EMA starts evaluating COVID-19 medicine

Portfolio
The European Medicines Agency (EMA) has started evaluating the anti-inflammatory medicine RoActemra (tocilizumab) to extend its use to include treatment of hospitalised adult patients with severe COVID-19 who are already receiving treatment with corticosteroids and require extra oxygen or mechanical ventilation (breathing assisted by a machine).
gyógyszertár

RoActemra is considered a potential treatment for COVID-19 because of its ability to block the action of interleukin-6, a substance produced by the body’s immune system in response to inflammation, which plays an important role in COVID-19.   

EMA’s human medicines committee (CHMP) will carry out an accelerated assessment of the data submitted in the application, including results from four large randomised studies in patients hospitalised with severe COVID-19, to decide whether the extension of indication should be authorised.

The CHMP's opinion, together with any requirements for further studies and additional safety monitoring, will then be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.

EMA will communicate on the outcome of its evaluation, which is expected by mid-October unless supplementary information is needed.

About RoActemra

RoActemra is a medicine used to treat:

  • adults with severe rheumatoid arthritis that is getting worse in patients who have not been previously treated with a medicine called methotrexate;
  • adults with moderate to severe active rheumatoid arthritis whose previous treatments with disease modifying antirheumatic drugs (DMARDs), such as methotrexate or medicines known as tumour necrosis factor (TNF) blockers, have not worked well or were not tolerated;
  • children from 1 year of age with active systemic juvenile idiopathic arthritis in whom other treatments (with anti-inflammatory medicines called NSAIDs and corticosteroids) have not worked well enough;
  • children from 2 years of age with juvenile idiopathic polyarthritis in whom treatment with methotrexate has not worked well enough.

RoActemra is used in combination with methotrexate for these conditions but it can be used on its own in patients for whom methotrexate is inappropriate.

RoActemra is also used to treat adults with giant cell arteritis, a disease in which arteries, usually of the head, are swollen.

RoActemra can also be used in adults and children from 2 years of age for the treatment of severe or life-threatening cytokine release syndrome (CRS, a condition that can cause nausea, vomiting, pain and low blood pressure). CRS is a side effect of certain cancer treatments and RoActemra is used for CRS caused by chimeric antigen receptors (CAR) T-cell medicines.

RoActemra contains the active substance tocilizumab.

RoActemra was first authorised in the EU in 2009. More information about the medicine is available on the EMA website.

More in Economy

May 24, 2022 17:25

One of the largest automotive suppliers of Germany to open office in Budapest

Kostal Group to initially employ 360 highly-skilled workers in Business Service Center

orbán viktor
May 24, 2022 16:55

Viktor Orbán: I have never seen such uncertainty in the world

The Prime Minister also spoke about several challenges

olajvezetek
May 24, 2022 15:25

Hungary's Orbán rejects discussion on Russian oil embargo at EU summit

Financial Times cites Orbán's letter to European Council President

Évente átlagosan 130 ezer forintért vásárolunk az interneten
May 24, 2022 13:35

One of Europe's leading online fashion stores enters Hungary

Zalando now available

virág_barnabás_mnb
May 24, 2022 12:02

Hungary central banker says base rate could be raised at half the current pace

It is impossible to offset upward pressure on prices in the short term by raising interest rates - Virág